894413-82-2

Upstream product

• 103-19-5 di(p-tolyl) disulfide 

Downstream Products

• 1322084-12-7 (1-{4-[4-(4-ethoxycarbonylmethyl-3,5-diethyl-pyrazol-1-ylmethyl)-phenyldisulfanyl]-benzyl}-3,5-diethyl-1H-pyrazol-4-yl)-acetic acid ethyl ester 
• 1322084-13-8 [3,5-diethyl-1-(4-methoxysulfinyl-benzyl)-1H-pyrazol-4-yl]-acetic acid ethyl ester 
• 1322084-15-0 {1-[4-(3-chloro-4-methyl-phenylsulfamoyl)-benzyl]-3,5-diethyl-1H-pyrazol-4-yl}-acetic acid ethyl ester 
• 1322084-16-1 C₂₃H₂₆ClN₃O₄S 
• 1322084-14-9 {1-[4-(3-chloro-4-methyl-phenylsulfinamoyl)-benzyl]-3,5-diethyl-1H-pyrazol-4-yl}-acetic acid ethyl ester 
• 99094-78-7 2-amino-3-(4-mercaptophenyl)propanoic acid hydrochloride 
• 88170-93-8 N-boc-2-amino-3-(4-mercaptophenyl)propanoic acid 
• 100538-31-6 1,2-bis[4-(formyl)phenyl]disulfane 

Relevant academic research and scientific papers

COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES

Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one oximine, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.

PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS

The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity, wherein W, L1, L2, X, L3, Y, R1 and R2 are as defined in the spe

PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS

The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity, wherein W, L1, L2, X, L3, Y, R1 and R2 are as defined in the spe